



## **LOPHOS CONFIRMS APPEARANCE AT BENZINGA CAPITAL CONFERENCE IN HOLLYWOOD, FLORIDA AND FINALIZES ANNUAL GENERAL MEETING**

**Napanee, Ontario, February 28, 2024** – Lophos Holdings Inc. ("Lophos", or the "Company") (CSE:MESC) is thrilled to announce its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., will participate in the upcoming Benzinga Capital Conference, scheduled to take place in Hollywood, Florida, on April 16-17, 2024. Lophos will be showcasing their latest achievements and initiatives during the event.

The Benzinga Cannabis Capital Conference is a premier event that brings together industry leaders, investors, and entrepreneurs to discuss the latest trends, opportunities, and challenges in the rapidly evolving cannabis and psychedelic sectors. This event presents an excellent platform for Lophos to connect with potential investors, collaborators, and stakeholders.

"We are thrilled to participate in the Benzinga Capital Conference for the third year and to continue to showcase our innovative approaches in the psychedelic sector," said Claire Stawnyczy, CEO at Lophos Pharmaceuticals. "This conference provides an invaluable opportunity for us to engage with investors, share our vision, and highlight our progress in developing therapeutics solutions."

In addition to its participation in the conference, Lophos Holdings Inc. is also pleased to announce its upcoming Annual General Meeting (AGM), scheduled for March 28, 2024. The AGM will provide shareholders with an opportunity to review the company's performance, vote on important matters, and engage with the management team.

"We look forward to welcoming our shareholders at our upcoming Annual General Meeting," added Claire Stawnyczy, "This event will enable us to provide a comprehensive update on our business activities, financial performance, and strategic initiatives. We encourage all shareholders to participate and contribute to the ongoing success of Lophos."

For further details, please visit our website at <https://lophos.com> and connect with us on Twitter (@lophospharma) and LinkedIn for the latest updates and insights.

## **About Lophos**

Lophos Pharmaceuticals Corp., a wholly-owned subsidiary of Lophos Holdings Inc. (CSE:MESC), stands as a prominent biosciences company specializing in the cultivation, research, and sale of peyote. Distinguished by its Controlled Substances Dealers License (CSDL), the subsidiary is authorized for the possession, sale, sending, transportation, and delivery of various controlled substances, including mescaline, psilocin, psilocybin, LSD, DMT, MDMA, and ketamine. Additionally, the license grants permission for the production of mescaline, psilocin, and psilocybin, showcasing the comprehensive scope of our operations.

### **For further inquiries:**

Director: Claire Stawnyczy, CEO, Lophos Holdings Inc.

Contact: Giselle Barona

Email: [invest@lophos.com](mailto:invest@lophos.com)

Website: [www.lophos.com](http://www.lophos.com)

Phone: 1-833-450-7407

### **Cautionary Statement**

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lophos' current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company's peyote cactus product development. Forward-looking information is based on reasonable assumptions that have been made by Lophos at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Lophos is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Lophos' final long form prospectus dated August 11, 2023, which is available on Lophos's profile at [www.sedarplus.ca](http://www.sedarplus.ca).

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

###